← Search & browse all drugs
RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Substituted alkylamines
brompheniramine
R06AB01
Forms & Strengths
- Tablets 2 mg
- Tablets 4 mg
- Syrup 2 mg/5 mL
- Injectable solution 10 mg/1 mL
Adult Dosing
- 2–4 mg PO q4–6 h
- Max 24 mg/day PO
- 10 mg IV/IM single dose for severe symptoms
Pediatric Dosing
- ≥6 y: 1–2 mg PO q4–6 h, max 6 mg/day
- 2–5 y: 0.5–1 mg PO q4–6 h, max 3 mg/day
- <2 y: not recommended
Indications
- Allergic rhinitis (seasonal/perennial)
- Acute urticaria
- Allergic conjunctivitis
- Pruritus due to insect bites or dermatitis
- Symptomatic relief of common cold
Mechanism of Action
- Reversible competitive H1‑receptor antagonist
- Blocks histamine‑mediated vasodilation and increased capillary permeability
- Exerts mild anticholinergic effects
Contraindications
- Known hypersensitivity to brompheniramine or any formulation component
- Concomitant use of monoamine‑oxidase inhibitors (MAOIs)
- Neonates and infants <2 years
Adverse Reactions
- Sedation and drowsiness
- Dry mouth, blurred vision, urinary retention (anticholinergic)
- Tachycardia or palpitations
- Hypotension or orthostatic dizziness
- Nausea, vomiting, constipation
- Headache
- Paradoxical excitation in children
Drug Interactions
- Additive CNS depression with alcohol, opioids, benzodiazepines, barbiturates
- Increased anticholinergic burden with other anticholinergics (e.g., TCAs, antispasmodics)
- Hypertensive crisis risk with MAOIs
- Additive sedation with other H1 antihistamines
- Potential QT‑prolongation additive effect with other QT‑prolonging drugs
Curated Content: Needs Vetting Before Put to Clinical Use